Alice P. Chen, MD | Authors

The Maze of PARP Inhibitors in Ovarian Cancer

February 10, 2012

The development of poly(ADP-ribose) polymerase (PARP) inhibitors as a new class of anticancer agents has created a tremendous amount of hope in the ovarian cancer community, especially in the high-risk, difficult-to-screen, hereditary ovarian cancer population.